Discover 1,249 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,249
Active & Responsive
Study of GalaFLEX LITE™ Scaffold in Treatment of Capsular Contracture After Breast Implant Augmentation
for
Capsular Contracture Associated With Breast Implant,
Location: Nashville TN, Alpharetta GA, Atlanta GA,
Sponsor: C. R. Bard
Sex: Female
Age: 22 - 70
Code: NCT05945329
Recruiting
Active & Responsive
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
for
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC,
Location: Nashville TN, Huntsville AL, Atlanta GA, Germantown TN,
Sponsor: Immuneering Corporation
Sex: All
Age: 18+
Code: NCT07562152
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
for
Triple Negative Breast Neoplasms
Location: Nashville TN, Athens GA, Hattiesburg MS, Mobile AL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06841354
Phase3, Recruiting
Active & Responsive
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Nashville TN, Indianapolis IN, St Louis MO, Chicago IL,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05216432
Phase1, Recruiting
Active & Responsive
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
for
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer,
Location: Nashville TN, St Louis MO, Chicago IL, New Orleans LA,
Sponsor: Cogent Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT07361562
Phase1, Recruiting
Active & Responsive
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Nashville TN, Knoxville TN, Atlanta GA, Indianapolis IN,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase3, Recruiting
Active & Responsive
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
for
Percutaneous Coronary Intervention,
Location: Nashville TN, Huntsville AL, Jackson TN, Owensboro KY,
A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
for
AML, MDS
Location: Nashville TN, Atlanta GA, Chapel Hill NC, Detroit MI,
Sponsor: TScan Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05473910
Phase1, Recruiting
Active & Responsive
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
for
Breast Cancer, Endometrial Cancer, Ovarian Cancer,
Location: Nashville TN, St Louis MO, Huntersville NC, Zion IL,
Sponsor: Terremoto Biosciences Inc.
Sex: All
Age: 18+
Code: NCT07109726
Phase1, Phase2, Recruiting
Active & Responsive
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
for
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Location: Nashville TN, Oklahoma City OK, Huntersville NC,
Sponsor: Phanes Therapeutics
Sex: All
Age: 18+
Code: NCT05431270
Phase1, Phase2, Recruiting
Active & Responsive
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
for
Non-Small Cell Lung Cancer, NSCLC,
Location: Nashville TN, Charlotte NC, Fairfax VA, Houston TX,